NCT07558798Not yet recruiting
Vexus Assessment and Natriuresis-guided Diuretic Therapy in Acute Heart Failure
Source: ClinicalTrials.gov · Last updated 30 Apr 2026
Brief summary (registry, in English)
This study evaluates whether natriuresis-guided diuretic therapy improves outcomes in patients with acute heart failure (AHF) and severe congestion. All patients hospitalized with AHF will be screened using Venous Excess Ultrasound (VExUS) and randomized 1:1 to either natriuresis-guided escalation of loop diuretics or standard care. The primary endpoint, evaluated in patients with VExUS grade 3 (severe congestion), is a hierarchical composite (win ratio) of 90-day mortality, 90-day rehospitalization, and hospital length of stay. Key secondary endpoints (hierarchical) include (1) difference in win ratio between patients with VExUS 3 versus VExUS 0-2 at hospital admission (assessed by interaction testing and statistically tested only if the primary endpoint is significant) and (2) win ratio (primary endpoint) tested among patients with VExUS 0-2 at hospital admission (statistically tested only if the first key seconday endpoint is significant). Exploratory endpoints include in-hospital clinical, hemodynamic, and biochemical outcomes (mortality, eGFR, NT-proBNP, NYHA class, VExUS score, natriuresis/diuresis, and patient-reported dyspnea), associations between congestion markers (VExUS, FibroScan, lung ultrasound, clinical score, and NT-proBNP), as well as quality of life at 90 days, GDMT optimization score at discharge, and long-term time to readmission and mortality assessed through registry linkage.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 270 (estimated)
- First submitted
- 7 Apr 2026
- Start date
- 1 Apr 2026
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- University Hospital, Akershus
- Diseases
- Heart failure
- NCT number
- NCT07558798
What you commit to
- Study type: Interventional
- Planned participants: 270
- From 1 Apr 2026 to the primary completion date, 31 Dec 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Dyspnea primarily due to non-cardiac causes
Lab values
- Advanced renal disease or estimated glomerular filtration rate (eGFR) \< 20 mL/min/1.73m2 at screening or on-going dialysis.
Other
- Enrollment in another study interfering with the treatment algorithm of the current study
- Inability to follow the treatment protocol
- Language barriers requiring the need for an external interpreter
- Pregnant or nursing (lactating) women
- Very short life expectancy (\<30 days)
Who the study is looking for
- Age \>18 years
- Hospitalization with AHF, either de novo or worsening of chronic HF
- Able to provide written informed consent
- Requirement of intravenous loop diuretic treatment as judged by the treating physician
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Akershus University Hospital Coordinator of this site? Confirm its status | Lørenskog | Norway | Unknown status |
| Østfold Hospital Trust Coordinator of this site? Confirm its status | Sarpsborg | Norway | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.